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Introduction: Atrial ﬁbrillation (AF), one of the major risk factors for stroke, imposing a substantial burden to the
Swedish health care system. Apixaban has demonstrated superiority towarfarin and aspirin in stroke prevention
amongst patientswith AF in two large randomised clinical trials. The aimof this studywas to assess the economic
implications of apixaban against warfarin and aspirin in these patients from a Swedish societal perspective.
Materials and Methods: A Markov cohort model was constructed to characterise the consequences of anticoagu-
lant treatment with regards to thromboembolic and bleeding events, as well as the associated health care costs,
life-years and quality-adjusted life years (QALYs) for patients with AF treated with apixaban, warfarin or aspirin.
Incremental cost-effectiveness ratios (ICERs) per QALY gained of apixaban relative to warfarin (among patients
suitable for warfarin treatment) and aspirin (among patients unsuitable for warfarin treatment)were calculated.
Costs (in 2011 SEKs) and QALYs were discounted at 3% per annum.
Results: The model estimated the ICER of apixaban versus warfarin amongst patients who are suitable for
warfarin therapy to be SEK 33,458/QALY gained and that of apixaban versus aspirin amongst those unsuitable
for warfarin therapy to be SEK 41,453/QALY gained. Probabilistic sensitivity analyses indicate that apixaban is
an optimal treatment option compared with warfarin and aspirin, when the willingness-to-pay is above SEK
35,000 and SEK 45,000 per QALY, respectively.
Conclusions:Apixabanwas found to be a cost-effective alternative towarfarin and aspirin for stroke prevention in
patients with AF in Sweden.© 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).Introduction
In Sweden, 3.2% of the adult population (≥20 years) is diagnosed
with atrial ﬁbrillation (AF), [1–3] with this ﬁgure rising to above 10%
in those aged 75–90 years (13.4% in age group 80–89 years). [1,4]agulant; INR, International nor-
C, Novel oral anticoagulant;
er Thromboembolic Events in
licylic Acid to Prevent Strokes;
lvular atrial ﬁbrillation; QALY,
I, Myocardial infarction; ICH,
on-major; CV, Cardiovascular;
uroQol 5 dimensions; ICER,
therapeutic range; CEAC, Cost-
s),
cobson@bms.com (L. Jacobson),
. This is an open access article underSuch individuals are around 2.6 times more likely than the general
population to have a stroke,[5] with a ﬁrst stroke being associated
with longer hospital stay, increased costs, increased risk of in-hospital
medical complications, and twice the likelihood to be fatal among pa-
tients with AF compared to those without AF.[6,7] Despite evidence
that the incidence of AF-related stroke in Sweden has declined (e.g.,
from 9.1% to 7.2% between 1987–1991 and 2002–2006), [5] it still im-
poses a substantial burden to the country’s health care system. The total
cost of AF in Sweden has been estimated to be €708 million per annum
(2007 prices), with €209 million of this being attributable to stroke. [8]
This situation invites questions about how well stroke prevention
measures for AF used in Sweden meet the needs of the population. Cur-
rent standard of care in Sweden involves the use of oral anticoagulant
(OAC) therapy, with data from the Swedish prescription registry
showing that warfarin is the most commonly used OAC. Noteworthy,
only 42%–46% of patients are treated with warfarin, although more than
80%have been identiﬁed as having risk factorsmotivating anticoagulation
therapy. [2,4] The remainder of patients diagnosed with AF are treated
with aspirin (37%) or are untreated (20%). [4,9] In addition, women are
less often treatedwithwarfarin thanmen at all ages (37% versus 46%). [4]the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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Sweden is quite high,with over 76.2% of patients on established therapy
being within the treatment range of an international normalised ratio
(INR) target of between 2.0 and 3.0, [10] with time in therapeutic
range (TTR) increasing with age.[10] However, these data need to be
considered alongside the well-known limitations of warfarin therapy, in-
cluding the need for frequent INR monitoring, various food and drug in-
teractions and implications of treatment interruptions. [11,12] A
retrospective, nationwide Danish cohort study showed that among
warfarin-treated patients, 72% had at least one treatment interruption
with a median duration of 36 days, with 49% of the thrombo-embolic
events or deaths occurring during those treatment interruptions. [12]
Similarly, a Swedish study examining the impact of a transient period of
worsened INR control among warfarin-treated patients, highlighted that
even short periods with an altered INR control can be expected to have
an impact on remaining life expectancy and quality-adjusted life expec-
tancy. [11]
Alongside the limitations with warfarin therapy, there are limita-
tions associated with aspirin treatment in patients who are unsuitable
for warfarin therapy, not least that it has been shown to have no advan-
tage over no treatment in preventingAF-related stroke. [13,14] Rather, a
Swedish registry study showed that treatment with aspirin was associ-
ated with higher risk of ischaemic stroke and thrombo-embolic events
compared with no antithrombotic treatment. [14]
The downsides associated with current treatment for AF in Sweden
make it crucial to know what place new and recently introduced OACs
have in this setting. These treatments belong to two drug classes: direct
thrombin inhibitors, such as dabigatran; and the oral factor Xa inhibitors,
including rivaroxaban and apixaban. The novel oral anticoagulants
(NOACs) offer some obvious advantages over warfarin in that they do
not requiremonitoring of INRor havewarfarin’s extensive range of inter-
actions with food and drugs. [7,15] Also of note, although none of these
have been directly compared in head-to-head trials, data from indirect
treatment comparisons have indicated that apixaban lowers the risk of
major bleeding compared with dabigatran and rivaroxaban. [16–18]
This key ﬁnding reﬂects direct evidence in support of apixaban from
two studies: the Apixaban for Reduction in Stroke and Other Thrombo-
embolic Events in Atrial Fibrillation (ARISTOTLE) trial [19] and the
Apixaban versus Acetylsalicylic Acid to Prevent Strokes (AVERROES)
trial. [20] In ARISTOTLE, apixaban reduced the risk of stroke or systemic
embolism (SE) compared with warfarin (hazard ratio [HR] 0.79, 95%
conﬁdence interval [CI], 0.66 to 0.95; P = 0.01), the risk of all-cause
death (HR 0.89; 95% CI, 0.80 to 0.99; P = 0.047) and was associated
with fewer adverse events such as major bleeding (HR 0.69, 95% CI
0.60 to 0.80; P b 0.001). [19] In addition, a recent analysis of the
ARISTOTLE trial revealed that the advantages of apixaban over warfarin
with regards to the risks of stroke or SE and bleeding, remain consistent
across different levels of INR control. [21] Therefore, evenwhen thequal-
ity of INR control is high, as in Sweden, [10,22] apixabanmight still offer
better clinical outcomes thanwarfarin. Similarly, in AVERROES, apixaban
reduced the risk of stroke or SE compared with aspirin in patients with
AF who were unsuitable for warfarin therapy (HR 0.45; 95% CI 0.32 to
0.62, P b 0.001), crucially, without a signiﬁcant increase in major bleed-
ing events (HR 1.13, 95% CI 0.74 to 1.75; P = 0.57). [20]
Consequently, apixaban offers efﬁcacy and safety advantages over
warfarin and aspirin for preventing AF-related strokes. The primary ob-
jective of this study was to evaluate the cost-effectiveness of apixaban
comparedwithwarfarin and apixaban comparedwith aspirin, in patients
with non-valvular AF (NVAF) from the societal perspective in Sweden.
Materials and Methods
Model Design
This study used a Markov cohort model approach to characterise
the consequences of anticoagulant treatment with regards tothromboembolic and bleeding events, as well as the associated health
care costs, life years and quality-adjusted life years (QALYs) for patients
with AF in Sweden. The model has previously been described in detail.
[23]
The model follows two populations of patients—those who are suit-
able forwarfarin treatment and those unsuitable—through the course of
their disease in six-week cycles. The unsuitable population in themodel
is deﬁned as patients who have demonstrated to be unsuitable (i.e.,
failed warfarin treatment) or are expected to be unsuitable (e.g., the
risk of stroke ismoderate or patientswhodo notwant to takewarfarin),
consistent with the AVERROES trial. [20]
During their time in the model, patients can transition amongst the
following mutually exclusive health states depending on which treat-
ment they are taking: NVAF on anticoagulant treatment; ischaemic or
unspeciﬁed stroke (referred hereafter as ‘ischaemic stroke’); SE,
myocardial infarction (MI); intracranial haemorrhage (ICH) further
segregated into haemorrhagic strokes and other ICHs; other major
bleed; clinically relevant non-major (CRNM) bleed; cardiovascular
(CV) hospitalisation unrelated to strokes, SE, MI or bleeding events
(other CV hospitalisation); ‘NVAF with subsequent aspirin treatment’
or death.
Event Risks and Transition Probabilities
Inputs on patient characteristics aswell as clinical event rates for pa-
tients suitable and unsuitable for warfarin treatment were obtained
from the ARISTOTLE and the AVERROES trials, [19,20] respectively, as
detailed in an earlier publication of themodel. [23] Baseline characteris-
tics and clinical event rates are displayed in Table 1.
Themodel was further adapted to the Swedish setting by using age-
and gender-speciﬁc general Swedish life tables, [24] treatment patterns,
local unit cost data and utilities as outlined in the sections below. Health
and cost outcomeswere discounted at 3.0% per annum, in-keepingwith
Swedish guidelines. [25]
Treatment Patterns
Patients can discontinue treatment and transition to the ‘NVAF with
subsequent aspirin treatment’ state, on the occurrence of bleeding
events or other discontinuation unrelated to the events modelled.
After experiencing other intracranial haemorrhages, 56% of the patients
treated with apixaban or warfarin were assumed to discontinue treat-
ment (i.e., transitioned to the ‘NVAFwithout anticoagulation treatment’
state). The remaining 44% had treatment interruption for six weeks and
transitioned back to the NVAF state, [26] whilst after the occurrence of
other major bleeds the same assumption as in Sorensen et al. (2009)
[27]was employed, inwhich 25% of the patients had discontinued treat-
ment. On the occurrence of CRNM bleeds, patients were assumed to re-
main on their current treatment, thus, to transition back to the NVAF
health state and be at risk for the clinical events modelled. Patients
treated with aspirin were assumed to remain on treatment on the oc-
currence of any bleeding events. Upon the occurrence of stroke or SE,
patients treated with apixaban or warfarin were assumed to continue
on their initial treatments. Patients treated with aspirin or second-line
aspirin were assumed to switch to warfarin only if they were suitable
for warfarin treatment, otherwise, they were assumed to continue on
aspirin. Upon the occurrence of a hemorrhagic stroke or MI, patients
were assumed to discontinue the treatment permanently.
Perspective
The societal perspective was adopted for the purposes of this analy-
sis, including both direct medical costs and municipality or community
care costs associated with care of medical events. As the starting age of
the cohort was 70, work productivity losses were not incorporated.
Table 1
Demographic characteristics and clinical event rates by treatment.
Warfarin-suitable Warfarin-unsuitable Source
Patient Characteristics (N/Min–Max)
Starting age 70 (63–76) 70 (48–100) [19,20]
Gender
% males 64.7% (11,785) 58.5% (3,277) [19,20]
% females 35.3% (6,416) 41.5% (2,321) [19,20]
CHADS2 distribution
CHADS2: 0–1 34.0% (6,183) 38.2% (2,142) [19,20]
CHADS2: 2 35.8% (6,516) 35.2% (1,973) [19,20]
CHADS2: 3–6 30.2% (5,502) 26.6% (1,483) [19,20]
Average CHADS2 score 2.1 2.0
Clinical event rates (per 100 patient years)
Apixaban Warfarin Apixaban Aspirin
Ischaemic stroke
CHADS2: 0–1 0.52 (31) 0.46 (27) 0.83 (10) 1.41(17) [23]
CHADS2: 2 0.95 (57) 0.93 (56) 1.53 (18) 3.36 (36) [23]
CHADS2: 3–6 1.53 (74) 1.94 (92) 1.96 (15) 5.20 (44) [23]
Average stroke rate 0.98 (162) 1.08 (175) 1.37 (43) 3.10 (97) [23]
Intracranial haemorrhage 0.33 (52) 0.80 (122) 0.34 (11) 0.35 (13) [23]
Other major bleed 1.79 (274) 2.27 (340) 1.07 (34) 0.57 (18) [23]
Clinically relevant non-major bleed 2.08 (318) 2.99 (444) 3.11 (96) 2.37 (84) [23]
Myocardial infarction 0.53 (90) 0.61 (102) 0.76 (24) 0.89 (28) [23]
Systemic embolism 0.09 (15) 0.10 (17) 0.06 (2) 0.41 (13) [23]
Other cardiovascular hospitalisation 10.46 10.46 10.46 12.09 [23]
Other treatment discontinuation 13.18 (2,047) 14.41 (2,182) 17.31 (495) 19.01 (537) [23]
Other death 3.08 (528) 3.34 (568) 2.97 (94) 3.59 (114) [23]
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Direct medical costs and costs of social services, reﬂected in 2011
Swedish kronor (SEK), were applied in the model as detailed in
Table 2. The daily costs of apixaban, warfarin and aspirin used were
SEK 20.82, SEK 2.16 and SEK 1.20, respectively. [28] These were based
on an average dose of apixaban 5 mg twice daily, warfarin 5 mg daily
and aspirin 75 mg twice daily, similarly to those used in the respective
trials. [19,20] The annual average cost of INR monitoring, calculated as
the proportional sum of monitoring conducted both in anticoagulant
clinics and primary care units,was estimated to be SEK 4,783 on average
per patient annually, assuming that each person had 16.66 monitoring
visits annually. [29]
Clinical event costs were divided into acute care costs and/or long-
term maintenance costs that were applied over the patients’ lifetime.
Costs of stroke were obtained from an incidence-based costing study
using the Riks-Stroke registry in Sweden. [30] The acute care cost of
stroke included ambulatory and ﬁrst hospitalisation-related costs that
occurred after the event. Long-termmaintenance costs formild tomod-
erate strokes were estimated as the average total cost of secondary pre-
vention, health care visits, additional hospitalisations and rehabilitation
observed annually for the ﬁrst four years after a stroke. For severe
strokes, community care costs were also included. Maintenance costs
were applied starting two weeks after the acute event and over a pa-
tient’s lifetime.
Acute care costs related to other ICH, MI, SE and other CV
hospitalisations were obtained from a regional price list used in Skåne,
[31] while costs for other gastrointestinal (GI) bleeds and CRNM bleeds
were micro-costed using Swedish treatment guidelines for patients
with GI complications and the regional price list used in Skåne and con-
ﬁrmed in discussions with two national experts. [31] The long-term
maintenance cost of MI was also obtained through discussion with ex-
perts. Long-term maintenance costs for SE were not available and so
were obtained by applying the ratio of acute SE costs over acute stroke
costs to the long-term maintenance costs of mild/moderate strokes.Utilities
Patients were assigned utilities according to their health states as
speciﬁed in Table 2. The baseline utility for AF patients was estimated
using the average EuroQol-5D (EQ-5D) index for the general population
aged 65–74 years (the average starting age used in the model), from a
population-based Swedish study, [32] and applying a decrement of
0.05 due to having AF, similarly to assumptions used in an earlier Swed-
ish cost-effectiveness model for AF. [33] The baseline utilities for stroke
and for haemorrhagic stroke were calculated by applying a reduction of
0.15 and 0.30, respectively, to the baseline utility for AF, based on esti-
mates from a 13-year follow-up study assessing the loss of quality-
adjusted life expectancy related to stroke events. [34] We assumed
that the utility of SE events would be equal to that of strokes, based on
suggestions that a post-minor stroke health statewouldmake a suitable
approximation of a post-SE health state. [35] Similarly, the baseline util-
ity forMI was estimated by applying a decrement of 0.19 to the baseline
utility for AF, based on the ﬁndings of a Swedish population-based study
that used the EQ-5D. [36]
In the model and as indicated in Table 2, utility decrements
(obtained from a UK-based utility catalogue [37]) were also applied
for a deﬁned period following the occurrence of the following
events: other ICHs; other major bleeds; CRNM bleeds; and other CV
hospitalisations that were unrelated to stroke, SE, MI and bleeding
events. The utility decrements associatedwith use of warfarin and aspi-
rinwere obtained froma time-trade-off study assessing a health state of
warfarin therapy consisting of monthly monitoring and alcohol interac-
tions and a health state of once daily aspirin use for AF. [38]
Analyses
The analyses in the study compared apixaban towarfarin among the
warfarin-suitable population, and apixaban to aspirin among the
warfarin-unsuitable population, over a lifetime horizon. The clinical
beneﬁt of apixaban was assessed as the estimated number of strokes
Table 2
Cost and utility inputs.
Cost Inputs
Cost in Swedish Kronor (95% Conﬁdence Interval) Diagnosis-related Group code; Source
Stroke or haemorrhagic stroke
Acute 100,213 (57,280 – 154,955) [30]
Maintenance mild/moderate (per month) 1,383 (791 – 2,139) [30]
Maintenance severe (per month) 24,293 (13,886 – 37,563) [30]
Other intracranial haemorrhage 46,123 (27,031 – 62,327) 014B;[31]
Other major bleed
Gastrointestinal bleed 38,899 (22,234 – 60,148) [47]
Non-intracranial, non-gastrointestinal-related bleed 14,790 (7,395 – 22,185) [48]
Clinically relevant non-major bleed 8,514 (4,257 –- 57,128) [47]
Myocardial infarction
Acute 100,257 (50,129 – 150,386) 121, 122,123,[31] 107A, 107B, 107C[49]
Maintenance (per month)a 148 (74 – 221) [28,31,42]
Systemic embolism
Acute 35,343 (20,201 – 54,649) 130,131[31,49]
Maintenance (per month) 488 (279 – 755) [30]
Other cardiovascular hospitalisation 26,265 (13,133 – 39,397) [31,49]
Annual cost of dyspepsia 2,330 [47]
Annual cost of renal monitoring 2,137 [31]
Utilities
Mean (95% Conﬁdence Interval) Source
Atrial ﬁbrillation 0.7450 (0.7 – 0.8) [32,33]
Ischaemic stroke 0.5950 (0.536 – 0.653) [32–34]
Systemic embolism 0.5950 (0.536 – 0.653)
Haemorrhagic stroke 0.4445 (0.387 – 0.504) [32–34]
Myocardial infarction 0.5550 (0.517 – 0.593) [32,33,36]
Utility decrements
Mean (95% Conﬁdence Interval) Duration Source
Other intracranial haemorrhage 0.1511 (0.081 – 0.238) 6 weeks [37]
Other major bleed 0.1511 (0.081 – 0.238) 2 weeks [37]
Clinically relevant non-major bleed 0.0582 (0.029 – 0.096) 2 days [37]
Other cardiovascular hospitalisation 0.1276 (0.081 – 0.182) 6 days [37]
Warfarin 0.0130 (0.00 – 0.047) While on warfarin [38]
Aspirin 0.0020 (0.00 – 0.006) While on aspirin
a The long-termmaintenance costs of MI included drug costs (i.e., for statins, beta-blockers, angiotensin-converting enzyme [ACE] inhibitors) the average of 1.5 cardiology visits in the
ﬁrst year post-MI and one primary care visit thereafter; ﬁgures also obtained through discussion with experts.
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andQALYs gained for each drug. In addition, themodel accrued andpre-
dicted lifetime costs,which consisted of anticoagulant andmanagement
costs, monitoring costs and event-related costs with associated cost-
offsets.
The relative clinical beneﬁt of apixaban versus warfarin and aspirin,
respectively, was assessed by calculating the incremental cost-
effectiveness ratio (ICER), which indicated whether the beneﬁt was ac-
crued within a willingness-to-pay threshold. Although no such ofﬁcial
threshold value exists in Sweden, guidelines by the National Board of
Health and Welfare mention that a cost per QALY below SEK 100,000
is considered low and a cost per QALY below SEK 500,000 is considered
moderate. Therefore, SEK 100,000 and SEK 500,000 per additional QALY
was used as the threshold values in the analysis of the results. [39]
In addition to the primary base case analysis, scenario analyses were
conducted to evaluate the robustness of the base case results. To do this,
changes were made in various parameters of the model and the
resulting effects were explored. Among the variables and assumptions
changed were:
1. Increasing/decreasing the baseline risk of stroke (i.e., by adjusting
baseline CHADS2 distribution)
2. The exclusion of treatment beneﬁts with respect tomortality (i.e., by
excluding mortality beneﬁts, unrelated to the events modelled, ob-
served over the duration of the clinical trial)3. Assumptions around treatment discontinuation (i.e., altering the risk
of treatment discontinuation to be 0 or equal amongst all compara-
tors beyond the trial periods rather than extrapolating treatment dis-
continuation rates through lifetime)
4. Allowing patients who are unsuitable for warfarin treatment to
switch to warfarin on the occurrence of stroke or SE events rather
than assuming they remain on their currently assigned treatment
(affecting only costs and utilities)
5. Adjusting the risks of stroke, ICH,major bleeding and CRNMbleeding
to reﬂect patients with well-controlled INR (i.e., by adjusting distri-
bution of a centre time in therapeutic range (cTTR) while keeping
all other parameters such as monitoring costs and utilities equal to
the base case)
6. Increasing/decreasing costs and utilities associated with stroke and
bleeding events and anticoagulant treatment
7. Increasing/decreasing the starting age of the cohort (without
adjusting baseline risk estimates to reﬂect ageing)
Probabilistic sensitivity analysis was carried out, in which input pa-
rameters were assigned a probability distribution and, thereby, varied
at random concurrently over 2,000 simulations of the model, chosen
as theminimum number of simulations required for results to converge
(i.e. remain invariable each time the probabilistic analysiswas run). This
allowed production of a scatter plot (i.e., cost-effectiveness plane) of the
additional gain in QALYs versus the additional cost for apixaban com-
pared with warfarin and aspirin, respectively. In addition, a cost-
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probability that apixaban would be considered the most effective alter-
native at a given threshold of willingness-to-pay for a QALY gained.
Results
Base Case Analysis
Comparedwith use ofwarfarin in a cohort of 1,000warfarin-suitable
patients, at an average age of 70 years, over a lifetime horizon, apixaban
was predicted to lead to 19 fewer strokes (ﬁrst and recurrent ischaemic
and haemorrhagic strokes) and SE events as well as 43 fewer major
bleeds (ﬁrst and recurrent haemorrhagic strokes, other ICH and other
major bleeds), resulting in 23 fewer CV-related deaths. The reduction
in these clinical events associated with apixaban therapy translated
into an additional 0.27 undiscounted life-years and an additional 0.21
discounted QALYs per patient. Treatment with apixaban over a lifetime
resulted in an additional discounted anticoagulant therapy and man-
agement cost of SEK 31,131; however, this costwas offset by the savings
of SEK 19,047 in monitoring costs and SEK 5,186 in clinical event-
related costs, resulting in an additional total discounted cost of SEK
6,898. The predicted ICER per QALY gained was SEK 33,458 (Table 3).
The base case analysis for the warfarin-unsuitable population in-
volved comparing outcomes in 1,000 patients treated with apixaban
with those in 1,000 patients, at an average age of 70 years, receiving as-
pirin. Patients who received apixaban were predicted to experience 70
fewer strokes (ﬁrst and recurrent ischaemic and haemorrhagic strokes)
and SE events leading to 56 fewer CV-related deaths. The model also
predicted that an additional 39 major bleeds (ﬁrst and recurrent
haemorrhagic strokes, other ICH and other major bleeds) and 39 CV
hospitalisations would occur with apixaban compared with aspirin.
The model predicted that apixaban therapy would lead to 0.44
undiscounted life-years gained and 0.29 discounted QALYs gained, at
an additional total discounted cost of SEK 12,183 (i.e., made up of addi-
tional anticoagulant andmanagement costs of SEK 27,972 and a cost off-
set of SEK 15,789 in clinical event costs). The resulting ICER was SEK
41,453 per QALY gained (Table 3).
Scenario Analyses
Several scenario analyses were performed to examine the cost-
effectiveness of apixaban against warfarin and aspirin, and the results
of these are provided in Table 4. The comparison between apixaban
and warfarin across all scenarios resulted in ICERs that varied between
being dominant (i.e., higher QALYs at lower costs) and SEK 79,652,
most inﬂuenced by assumptions surrounding monitoring costs and
the disutility associated with use of warfarin. The remainder of scenar-
ios had negligible impact on results. When compared to aspirin, the
ICERs from all scenarios varied between SEK 5,023 to SEK 74,246 per
QALY gained,most inﬂuenced by the baseline age of the cohort entering
the model.
In the base case analysis, treatment discontinuation rates from the
ARISTOTLE and the AVERROES trials were extrapolated over a lifetime
horizon, however, various assumptions around treatment discontinua-
tion rates were explored. Assuming that patients would not discontinue
the treatment after the trial period (i.e., treatment discontinuation risk
post the trial period = 0) had limited impact on the ICER of apixaban
relative to warfarin and increased the ICER of apixaban relative to aspi-
rin to SEK 51,372. In another scenario, where the discontinuation rates
for warfarin and aspirin post the trial period were set to be equal to
the rate for apixaban as observed in the clinical trials, no major differ-
ences were seen in the results. Similarly, exclusion of mortality beneﬁts
fromapixaban beyond those relating to eventsmodelled during the trial
period, and variation of the discount rates, had only limited impact on
the ICERs.Among the scenarios explored, a subgroup analysis that involved
setting CHADS2 score to ≥ 3, demonstrated that apixaban remained
cost-effective among patients with a high risk of stroke, with the associ-
ated ICERs being SEK 23,108 per QALY gained, when compared with
warfarin, and SEK 5,023 per QALY gained, when comparedwith aspirin.
Varying the starting age of patients entering the model between
60–80 years of age decreased/increased the ICER versus warfarin to
SEK 23,931 and SEK 44,407 per QALY gained, respectively. The ICER ver-
sus aspirin decreased/increased to SEK 14,301 and SEK 74,246 per QALY
gained, respectively. Variation of agewas correlated only to background
mortality but not to event risks, thus, differences in results can be attrib-
uted to increased/decreased life expectancy of the populationmodelled.
A scenario analyses exploring when the quality of INR control
among the warfarin-suitable patients was above the average (i.e.,
cTTR ≥ 76.51%), reﬂecting the clinical situation in Sweden, resulted in
an ICER of SEK 31,020, indicating that apixaban was cost-effective
over well-controlled warfarin.
Amongst scenarios varying the costs of events according to their
conﬁdence intervals, the ICER varied between SEK 27,326 and SEK
38,267 when compared to warfarin, and SEK 27,211 – SEK 52,621
when comparing to aspirin. Variations in utilities associated with the
health states according to their conﬁdence intervals had negligible im-
pact on results; however, variations in the disutility associated with
warfarin and aspirin treatment were more inﬂuential. Speciﬁcally, the
ICER of apixaban versus warfarin decreased to SEK 20,204 when the
utility decrement of warfarin was set to 0.047 (upper conﬁdence
limit) and increased to SEK 44,659 when the utility decrement was re-
duced to 0 (lower conﬁdence limit). Similarly, when the disutility asso-
ciated with aspirin was varied to 0.006 and 0, the ICER of apixaban
versus aspirin decreased to SEK 39,535 and increased to SEK 42,483,
respectively.
Probabilistic Sensitivity Analysis
Both cost-effectiveness planes (Figs. 1 and 3) indicated that apixaban
wasmore effective andmore costly thanwarfarin or aspirin inmost sim-
ulations. The CEACs (Figs. 2 and 4) show that apixaban had a higher
probability of being cost-effective compared with warfarin or aspirin
when the willingness-to-pay was approximately SEK 35,000 for
the warfarin-suitable population, and SEK 45,000 for the warfarin-
unsuitable population. At a willingness-to-pay threshold of SEK
100,000 and SEK 500,000 per QALY, apixaban was a cost-effective alter-
native compared towarfarin in 86% and 97% of simulations, respectively,
and in 84% and 99% of the model iterations when comparing to aspirin.
Discussion
Our study indicates that, from a Swedish societal perspective,
apixaban is a cost-effective treatment alternative towarfarin and aspirin
in a cohort of patientswith AF at an average age of 70 years. Speciﬁcally,
it found that apixaban was associated with fewer strokes than treat-
ment with warfarin or aspirin. Apixaban was associated with fewer
major bleeds in comparison towarfarin but a higher number in compar-
ison to aspirin (39 amongst a cohort of 1,000). Though the difference in
major bleeds was not statistically signiﬁcant between apixaban and as-
pirin in the AVERROES trial, [20] a higher number of major bleeds was
projected in the apixaban arm due to: 1) use of the difference in abso-
lute rates of major bleeds from the trial and 2) patients treated with
apixaban living longer, thus, exposed to the risk of major bleeding for
a longer period of time. Compared to warfarin as well as aspirin,
apixaban was deemed to cause net reduction in clinical events as ob-
served through increase in life expectancy and QALYs gained among
both patients forwhomwarfarin therapy either is or is not a suitable op-
tion. These health gains were associated with slightly increased costs,
attributed to increased anticoagulant costs, but also increased life-
expectancy in patients treated with apixaban, thus, incurring further
Table 4
Scenario analyses cost per QALY gained.
Scenario Warfarin-suitable
Patients
Warfarin-
unsuitable Patients
Apixaban Warfarin Apixaban Aspirin
Base case 33,458 41,453
Event risk (base case)
Patients with severe risk of stroke (CHADS2 score ≥ 3) (average CHADS = 2.1) 23,108 5,023
Exclusion of mortality beneﬁt for apixaban beyond that of events modelled during the trial period (include mortality beneﬁt) 35,988 45,924
Treatment discontinuation (base case)
Treatment discontinuation set to 0 beyond the trial period (treatment discontinuation observed in trial extrapolated through lifetime) 34,009 51,372
Treatment discontinuation rate for warfarin and aspirin patients set to be equal to that for apixaban patients beyond the trial period 32,687 40,886
Switch patterns
Switch to warfarin allowed after stroke/SE (patients remain on treatment) N/A 29,418
INR control
Adjusting the risks of stroke, ICH, major bleeding and CRNM bleeding to reﬂect patients with cTTR ≥ 76.51% 31,020 N/A
Discounting (base case)
Discount rate 0% (3%) 31,626 36,042
Discount rate 5% (3%) 34,691 45,481
Costs (base case)
Warfarin monitoring visit cost reduced by 50% to SEK 143.55 (from SEK 287.1) 79,652 N/A
Warfarin monitoring visit cost increased by 50% to SEK 430.65 (from SEK 287.1) Dominant N/A
Cost per monitoring visit N SEK 391 (SEK 287) Dominant N/A
Number of monitoring visits per year N 22.73 (16.66) Dominant N/A
Acute care costs for strokes decreased to SEK 57,280 (SEK 100,213) 37,039 49,615
Acute care costs for strokes increased to SEK 154,955 (SEK 100,213) 28,892 31,045
Monthly maintenance costs for mild/moderate stroke or haemorrhagic stroke decreased to SEK 791 (SEK 1,383) 34,242 46,618
Monthly maintenance costs for mild/moderate stroke or haemorrhagic stroke increased to SEK 2,139 (SEK 1,383) 32,459 34,866
Monthly maintenance costs for severe stroke or haemorrhagic stroke decreased to SEK 13,886 (SEK 24,293) 38,267 52,621
Monthly maintenance costs for severe stroke or haemorrhagic stroke increased to SEK 37,563 (SEK 24,293) 27,326 27,211
Cost of other intracranial haemorrhage decreased to SEK 27,031 (SEK 46,123) 34,339 41,379
Cost of other intracranial haemorrhage increased to SEK 62,327 (SEK 46,123) 32,710 41,515
Age (base case 70 years)
Start age 60 years 23,931 14,301
Start age 80 years 44,407 74,246
Utilities (base case)
Utility for ischemic stroke and systemic embolism decreased to 0.536 (0.595) 33,399 38,818
Utility for ischemic stroke and systemic embolism increased to 0.653 (0.595) 34,046 44,397
Utility for hemorrhagic stroke decreased to 0.387 (0.4445) 33,335 41,468
Utility for hemorrhagic stroke increased to 0.504 (0.4445) 33,584 41,437
Utility decrements
Other intracranial haemorrhage disutility decreased to 0.081 (0.1511) 33,470 41,451
Other intracranial haemorrhage disutility increased to 0.238 (0.1511) 33,443 41,454
Other major bleed disutility decreased to 0.081 (0.1511) 33,465 41,442
Other major bleed disutility increased to 0.238 (0.1511) 33,450 41,466
Clinically relevant non-major bleed disutility decreased to 0.029 (0.0582) 33,459 41,451
Clinically relevant non-major bleed disutility increased to 0.096 (0.0582) 33,457 41,454
Warfarin disutility decreased to 0 (0.013) 44,659 N/A
Warfarin disutility increased to 0.047 (0.013) 20,204 N/A
Aspirin disutility decreased to 0 (0.002) N/A 42,483
Aspirin disutility increased to 0.006 (0.002) N/A 39,535
N/A = not applicable
283T. Lanitis et al. / Thrombosis Research 134 (2014) 278–287costs over their extended lifetime. The resulting cost per additional
QALY was well below a willingness-to-pay threshold in Sweden of
SEK 500,000 and even below a threshold of SEK 100,000 (base case
ICERs: apixaban versus warfarin SEK 33,458 per QALY gained; apixabanTable 3
Lifetime base case results –mean life years, quality-adjusted life years and costs per patient.
Warfarin-suitable Population
Apixaban Warfarin N
Health outcomes (per patient)
Life years (undiscounted) 11.37 11.11 0
Quality-adjusted life years (discounted) 6.71 6.51 0
Costs (Swedish kronor discounted per patient)
Anticoagulants and management 36,666 5,535 3
Monitoring 2,225 21,272 −
Clinical event costs 84,470 89,656 −
Total 123,361 116,463 6
Swedish kronor per quality-adjusted life year gained 33,458
a Slight deviations are observed in the differences due to roundingversus aspirin SEK 41,453 per QALY gained in warfarin-unsuitable
patients).
Moreover when compared to a cohort of patients who are well con-
trolled on warfarin reﬂecting Swedish practice, our model predicted aWarfarin-unsuitable Population
et (apixaban–warfarin)a Apixaban Aspirin Net (apixaban–aspirin)a
.27 11.36 10.92 0.44
.21 6.70 6.41 0.29
1,131 32,044 4,071 27,972
19,047 - - -
5,186 93,356 109,145 −15,789
,898 125,400 113,216 12,183
41,453
Fig. 1. Cost-effectiveness plane for the warfarin-suitable population.
284 T. Lanitis et al. / Thrombosis Research 134 (2014) 278–287reduced ICER of SEK 31,020 per QALY gained. This can be attributed to
the beneﬁts of apixaban compared to warfarin in stroke prevention
and bleeding being maintained across ranges of centres’ and patients’
predicted quality of INR control, as demonstrated by an earlier analysis
of the ARISTOTLE trial. [21] This study highlighted that even in the
highest cTTR quartile where patients were well controlled on warfarin,
the hazard ratios of apixaban versuswarfarin for stroke or SE andmajor
bleeds were 0.88 (95% CI, 0.57 to 1.35) and 0.75 (95% CI, 0.58 to 0.97),
respectively. Additionally,well controlled patients experience a reduced
number of events; this led to improved life-expectancy in both the
apixaban and warfarin arms in our analysis. This coupled with the con-
sistent treatment effect for apixaban subsequently led to improved
QALY gains and a lower ICER.
Various scenario analyses demonstrate that the cost-effectiveness of
apixaban versus warfarin wasmaintained even after varying key model
parameters including varying the disutility associated with warfarin by
its conﬁdence intervals resulting in an ICER ranging between SEK
20,204 and 44,659 per QALY gained. The ICER of apixaban versuswarfa-
rinwasmost sensitive to assumptions surrounding the cost of INRmon-
itoring and the utility decrement associated with use of warfarin. Our
analysis demonstrated that when annual monitoring costs were set to
be above SEK 6,522, apixaban was cost-saving and a dominant alterna-
tive to warfarin. This estimate is lower than the annual monitoring cost
for patientsmonitored in primary care, [40] but higher than the cost es-
timated when adjusting for the distribution of monitoring conducted in
primary care and anticoagulation clinics, the latter being less expensive.
[41] Subsequently our analysis demonstrates that apixaban has theFig. 2. Cost-effectiveness acceptability curvepotential to be a dominant alternative to warfarin in different settings
of care depending on the frequency and cost of monitoring. Scenario
analysis varying the utility decrement of warfarin demonstrated that
apixaban remained a highly cost-effective alternative to warfarin even
when no utility decrement was associated with warfarin. Similarly, sce-
nario analysis on the ICER of apixaban versus aspirin demonstrated the
model projections were robust to changes in the inputs, with results
being most sensitive to varying the age of patients entering the model.
When the baseline age of patients entering the model was increased
to 80, reﬂecting an elderly population of patients treated with aspirin
as observed in retrospective studies, [14] apixaban remained cost-
effective at an increased ICER of SEK 74,246 per QALY gained. Recent
retrospective analysis using the National Swedish Patient registry
found that aspirin had ‘no discernible protective effect against stroke
and may increase risk of ischaemic stroke in the elderly’. [14] This
coupled with the recommended dose of aspirin in Sweden [42] being
lower than the average dose used in the AVERROES trial [20] (75 mg
versus 1–324 mg daily) would suggest that use of the risks obtained
from the AVERROES studymay overestimate the relative effects of aspi-
rin in comparison to the real-world Swedish patient population treated
with aspirin. Although this would suggest use of a slightly higher price
for aspirin, overestimates in efﬁcacy are likely to have offset this con-
tributing to a potentially higher predicted ICER for apixaban versus
aspirin.
Overall, assumptions utilised for surrounding input data were con-
servative favouring comparators. For example cost estimates for
treating stroke were based on an incidence-based study of all stroke-s for the warfarin-suitable population.
Fig. 3. Cost-effectiveness plane for the warfarin-unsuitable population.
285T. Lanitis et al. / Thrombosis Research 134 (2014) 278–287related hospitalisations in Sweden, [30] though there is evidence to sug-
gest that AF-related strokes aremore costly. [7] As demonstrated in sce-
nario analysis, increased costs of treating stroke events would improve
the cost-effectiveness estimates of apixaban versus warfarin and
aspirin.
Our study is the ﬁrst published cost-effectiveness evaluation of
apixaban for AF in Sweden. Its ﬁndings are in linewith economicmodels
of treatment for AF in other countries, which showed that compared
withwarfarin and aspirin, apixabanwas amore attractive treatment op-
tion from a payer’s perspective, being cost-effective and even a domi-
nant treatment option in some studies. [43–45]
An earlier Swedish health economic study found that dabigatran
was a cost-effective alternative to warfarin for stroke prevention in AF.
[33] Though our study used a similar model design, results are not di-
rectly comparable. Key differentiators in our study include detailed
modelling of mortality subsequently informing more robust estimates
of life expectancy and quality-adjusted life expectancy, which can sub-
stantially affect cost-effectiveness estimates. We assumed that all pa-
tients discontinuing treatment would receive aspirin second-line
treatment, whereas Davidson et al. [33] assumed that after discontinu-
ation from dabigatran therapy patients would switch to warfarin, aspi-
rin and no treatment in equal proportions, whereas after warfarin
therapy patients would switch to aspirin or no treatment. Had we
used the same assumption, ICER estimates would have improved asFig. 4. Cost-effectiveness acceptability curvespatients treated with apixaban would receive a second-line treatment
with superior stroke prevention powers (at a negligible additional
cost) in comparison to patients treated with warfarin or aspirin.
Though our base case assumption can be considered conservative in
comparison to the earlier Swedish evaluation, [33] the introduction of
NOACs could shift treatment practice. The most recent Swedish draft
treatment guidelines recommend the use of NOACs as an alternative
to warfarin for ﬁrst-line therapy in patients with AF. [46] The use of as-
pirin is discouraged in patients with a CHA2 DS2 VASc score of one or
above. [46] It is, therefore, possible that on discontinuation of ﬁrst-line
therapy patients will no longer receive aspirin or no treatment, but
could be offered an alternative NOAC. The implication of treatment
switching between NOACs was not examined due to lack of data to in-
form such treatment patterns as well as lack of evidence to inform the
risk of events when these drugs are used as a second-line treatment.
Although the key strength of our model is that its predictions of
treatment effects were based on large blinded clinical trials, this might
also mean that it could have overestimated the clinical beneﬁt of treat-
ment compared with outcomes in real-world settings. Furthermore,
given ARISTOTLE and AVERROES were multinational trials, clinical and
safety estimates were derived from multiple countries rather than
Sweden or the European countries speciﬁcally. However, the baseline
demographics of patients enrolled in ARISTOTLE andAVERROES, includ-
ing age and CHADS2, correspond to those observed in Swedish patientsfor the warfarin-unsuitable population.
286 T. Lanitis et al. / Thrombosis Research 134 (2014) 278–287with AF, [9,10,18] thus, considered representative for the purposes of
this study. Though results from our analysis were primarily based on re-
sults fromARISTOTLE andAVERROES trials, in absence of cost and utility
estimates derived from these trials, estimates ofmean costs and utilities
were obtained from previously published studies or price-lists. Subse-
quently estimatesmay not reﬂect the precise trial populations, however
chosen to approximate resource use and quality of life in a Swedish AF
population. Similarly, input data for costs were based on one regional
price list, [31] thus, potential variations in prices between regions may
exist. However, results from the scenario analysis highlighted that
apixaban maintained its cost-effectiveness regardless of variations in
costs.
Overall, our study demonstrates that apixaban is an economically
justiﬁable alternative for a cohort of patients with NVAF, at an average
age of 70, receiving care in Sweden, offering additional health beneﬁts
over warfarin and aspirin, at an acceptable cost for health payers.
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